Zevenbergen Capital Investments LLC Sells 1,796 Shares of Veeva Systems Inc. $VEEV

Zevenbergen Capital Investments LLC cut its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 109,731 shares of the technology company’s stock after selling 1,796 shares during the period. Zevenbergen Capital Investments LLC owned approximately 0.07% of Veeva Systems worth $31,323,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Burkett Financial Services LLC bought a new stake in Veeva Systems during the 3rd quarter valued at $27,000. SHP Wealth Management acquired a new position in shares of Veeva Systems during the fourth quarter valued at $26,000. MV Capital Management Inc. acquired a new position in shares of Veeva Systems during the fourth quarter valued at $30,000. Reflection Asset Management bought a new stake in shares of Veeva Systems during the fourth quarter valued at about $32,000. Finally, Compass Financial Management LLC acquired a new stake in Veeva Systems in the second quarter worth about $27,000. 88.20% of the stock is owned by institutional investors.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva Basics adoption is expanding. More than 175 emerging biotechs are using the preconfigured platform across clinical, regulatory, quality, medical, and commercial operations. The announcement supports Veeva’s ability to win customers early and expand them as they advance toward commercialization. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical-data automation is showing meaningful scale. Veeva says its Development Quality Solution has cleaned data for more than 1 million clinical-trial subjects across over 1,000 studies, highlighting customer usage and the potential for automation to improve retention and cross-selling. Veeva’s DQS Scales Data Automation Across 1,000+ Clinical Studies
• Positive Sentiment: Management is highlighting continued platform momentum. CEO Peter Gassner said nearly 200 customers are using Veeva Basics, while the upcoming R&D and Quality Summit will showcase AI tools and customer use cases involving Eli Lilly, Pfizer, Sanofi, UCB, and others. The event may reinforce Veeva’s positioning as an important software provider for modern drug development. Veeva Summit to Showcase AI Innovations
• Positive Sentiment: Technical momentum remains strong. Market commentary says VEEV is nearing several buy points as institutional money returns to software companies with sticky enterprise customers. Veeva’s entrenched position in pharma data and workflows is viewed as a potential AI-era advantage. Software Leader Veeva Systems Positioned To Hit Buy Points After Nearly Doubling

Veeva Systems Stock Performance

Shares of NYSE:VEEV traded up $2.28 during trading hours on Thursday, hitting $284.78. 921,680 shares of the company’s stock traded hands, compared to its average volume of 2,342,119. The company’s fifty day simple moving average is $259.17 and its two-hundred day simple moving average is $202.93. The company has a market cap of $46.11 billion, a price-to-earnings ratio of 46.84, a price-to-earnings-growth ratio of 1.21 and a beta of 0.93. Veeva Systems Inc. has a 52 week low of $148.05 and a 52 week high of $303.39.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. The business had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, analysts anticipate that Veeva Systems Inc. will post 6.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. TD Cowen boosted their price target on shares of Veeva Systems from $235.00 to $283.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Oppenheimer raised their price objective on shares of Veeva Systems from $225.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, August 17th. Mizuho boosted their target price on Veeva Systems from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Robert W. Baird upped their target price on Veeva Systems from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th. Finally, Barclays increased their price target on Veeva Systems from $275.00 to $315.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Nineteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Veeva Systems has a consensus rating of “Moderate Buy” and an average price target of $284.88.

Insider Buying and Selling at Veeva Systems

In other news, Director Priscilla Hung sold 750 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total transaction of $195,780.00. Following the sale, the director directly owned 3,242 shares of the company’s stock, valued at $846,291.68. The trade was a 18.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas D. Schwenger sold 36,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $250.23, for a total value of $9,008,280.00. Following the sale, the insider directly owned 19,449 shares of the company’s stock, valued at approximately $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 51,591 shares of company stock valued at $13,355,945. Corporate insiders own 10.60% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.